Evogen secures $3 Million in series B financing

Printer Print Email Email
New York: Evogen, a global diagnostics, biological collection and detection systems company, has received $3 million in series B financing round led by L Capital Partners, a venture capital firm based in New York. Evogen is the new name for Sceptor Industries and represents the merger of two complementary companies. Evogen's technology brings detection and diagnostics capabilities, previously limited to the laboratory, into the field which gives the company a significant advantage over existing detection systems. Evogen's affordable solutions save time and money. It eliminates days of waiting and the need to transport samples to a lab. Evogen makes detection faster, more affordable, easier, and leads to quicker answers for customers. Sean Reineke, President and CEO of Evogen and former President of Sceptor, says, "We have emerged as a global diagnostic company able to meet long-standing market needs for several gene-based detection systems. Our portfolio of technologies and applications allows us to further expand beyond the biodefense market into commercial markets, including clinical diagnostics, environmental testing and research." John Levy, a partner at L Capital Partners, and a member of Evogen's Board of Directors, says: "The recent merger represents a milestone and gives the company all the components needed to offer a complete system at more affordable prices. Evogen brings the platform and the instruments and Sceptor brings the expertise for aerosol collection and the systems integration for complex biological detection systems. We are building on the company's success as the market leader and L Capital is pleased to support the team as they grow organically and by acquisition."

siliconindia